Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

在为期 16 周的 BNT162b2 方案中,B 细胞和 T 细胞免疫与疫苗的强效反应存在时间关联

阅读:4
作者:Manon Nayrac,Mathieu Dubé,Gérémy Sannier,Alexandre Nicolas,Lorie Marchitto,Olivier Tastet,Alexandra Tauzin,Nathalie Brassard,Raphaël Lima-Barbosa,Guillaume Beaudoin-Bussières,Dani Vézina,Shang Yu Gong,Mehdi Benlarbi,Romain Gasser,Annemarie Laumaea,Jérémie Prévost,Catherine Bourassa,Gabrielle Gendron-Lepage,Halima Medjahed,Guillaume Goyette,Gloria-Gabrielle Ortega-Delgado,Mélanie Laporte,Julia Niessl,Laurie Gokool,Chantal Morrisseau,Pascale Arlotto,Jonathan Richard,Justin Bélair,Alexandre Prat,Cécile Tremblay,Valérie Martel-Laferrière,Andrés Finzi,Daniel E Kaufmann

Abstract

Spacing of BNT162b2 mRNA doses beyond 3 weeks raises concerns about vaccine efficacy. We longitudinally analyze B cell, T cell, and humoral responses to two BNT162b2 mRNA doses administered 16 weeks apart in 53 SARS-CoV-2 naive and previously infected donors. This regimen elicits robust RBD-specific B cell responses whose kinetics differs between cohorts, the second dose leading to increased magnitude in naive participants only. While boosting does not increase magnitude of CD4+ T cell responses further compared with the first dose, unsupervised clustering of single-cell features reveals phenotypic and functional shifts over time and between cohorts. Integrated analysis shows longitudinal immune component-specific associations, with early T helper responses post first dose correlating with B cell responses after the second dose, and memory T helper generated between doses correlating with CD8 T cell responses after boosting. Therefore, boosting elicits a robust cellular recall response after the 16-week interval, indicating functional immune memory.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。